Dr Andrew Mark Thompson

Selected publications and creative works (Research Outputs)

  • Thompson, A. M., Blaser, A., Palmer, B. D., Anderson, R. F., Shinde, S. S., Launay, D., ... Wan, B. (2017). 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 27 (11), 2583-2589. 10.1016/j.bmcl.2017.03.069
    Other University of Auckland co-authors: Brian Palmer, Adrian Blaser, Bob Anderson, Bill Denny
  • Thompson, A. M., O'Connor PD, Marshall, A. J., Yardley, V., Maes, L., Gupta, S., ... Franzblau, S. G. (2017). 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis. Journal of Medicinal Chemistry, 60 (10), 4212-4233. 10.1021/acs.jmedchem.7b00034
    Other University of Auckland co-authors: Bill Denny
  • Satam, V. S., Pedada, S. R., Kamaraj, P., Antao, N., Singh, A., Hindupur, R. M., ... Martin, D. (2017). Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis. Organic Process Research and Development, 21 (1), 52-59. 10.1021/acs.oprd.6b00331
    URL: http://hdl.handle.net/2292/33077
  • Smaill, J. B., Gonzales, A. J., Spicer, J. A., Lee, H., Reed, J. E., Sexton, K., ... Blaser, A. (2016). Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4- d ]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. Journal of Medicinal Chemistry, 59 (17), 8103-8124. 10.1021/acs.jmedchem.6b00883
    URL: http://hdl.handle.net/2292/32487
    Other University of Auckland co-authors: Jeffrey Smaill, Bill Denny, Julie Spicer, Brian Palmer, Adrian Blaser
  • Thompson, A. M., O'Connor PD, Blaser, A., Yardley, V., Maes, L., Gupta, S., ... Wan, B. (2016). Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. Journal of Medicinal Chemistry, 59 (6), 2530-2550. 10.1021/acs.jmedchem.5b01699
    URL: http://hdl.handle.net/2292/30023
    Other University of Auckland co-authors: Adrian Blaser, Bill Denny
  • Thompson, A. M., Blaser, A., Palmer, B. D., Franzblau, S. G., Wan, B., Wang, Y., ... Denny, W. A. (2015). Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy. Bioorganic & Medicinal Chemistry Letters, 25 (18), 3804-3809. 10.1016/j.bmcl.2015.07.084
    Other University of Auckland co-authors: Adrian Blaser, Bill Denny, Brian Palmer
  • Palmer, B. D., Sutherland, H. S., Blaser, A., Kmentova, I., Franzblau, S. G., Wan, B., ... Thompson, A. M. (2015). Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 58 (7), 3036-3059. 10.1021/jm501608q
    Other University of Auckland co-authors: Bill Denny, Brian Palmer, Adrian Blaser, Hamish Sutherland
  • Launay, D., Chatelain, E., Braillard, S., Gupta, S., Puri, S., Yardley, V., ... Thompson, A. (13/5/2013). Towards the identification of a back-up candidate for DNDI-VL-2098 to treat visceral leishmaniasis. Poster presented at WorldLeish 5:The Fifth World Leishmaniasis Congress, Porto de Galinhas, Brazil. Related URL.

Contact details

Primary location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 117
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand